Events

EU TalentOn second edition
SEP
Mon
09
SEP
Tue
10
SEP
Wed
11
SEP
Thu
12
SEP
Fri
13
SEP
Sat
14

This was 1 year ago

Location

Katowice Poland

University of Silesia (different venues)
Programmes
Health Climate, Energy, Mobility Agro-Food, Environment Enhancing EU R&I Missions

The European Commission in collaboration with Katowice (Poland) as European City of Science in 2024 organises the second edition of EU TalentOn. During EU TalentOn a group of selected researchers between the ages 21 and 35 years old, will work in a team to come up with the best scientific solutions for challenges linked to one of the five EU missions. The contest finale will take place between 9-14 September 2024 in Katowice.

The previous EU TalentOn edition took place in Leiden in 2022 and these were the projects.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.